Litcius/Paper detail

PPARα Inhibition Overcomes Tumor-Derived Exosomal Lipid-Induced Dendritic Cell Dysfunction

Xiaozhe Yin, Wenfeng Zeng, Bowen Wu, Luoyang Wang, Zihao Wang, Hongjian Tian, Luyao Wang, Yunhan Jiang, Ryan Clay, Xiuli Wei, Qin Yan, Fayun Zhang, Chunling Zhang, Lingtao Jin, Wei Liang

2020Cell Reports165 citationsDOIOpen Access PDF

Abstract

Dendritic cells (DCs) orchestrate the initiation, programming, and regulation of anti-tumor immune responses. Emerging evidence indicates that the tumor microenvironment (TME) induces immune dysfunctional tumor-infiltrating DCs (TIDCs), characterized with both increased intracellular lipid content and mitochondrial respiration. The underlying mechanism, however, remains largely unclear. Here, we report that fatty acid-carrying tumor-derived exosomes (TDEs) induce immune dysfunctional DCs to promote immune evasion. Mechanistically, peroxisome proliferator activated receptor (PPAR) α responds to the fatty acids delivered by TDEs, resulting in excess lipid droplet biogenesis and enhanced fatty acid oxidation (FAO), culminating in a metabolic shift toward mitochondrial oxidative phosphorylation, which drives DC immune dysfunction. Genetic depletion or pharmacologic inhibition of PPARα effectively attenuates TDE-induced DC-based immune dysfunction and enhances the efficacy of immunotherapy. This work uncovers a role for TDE-mediated immune modulation in DCs and reveals that PPARα lies at the center of metabolic-immune regulation of DCs, suggesting a potential immunotherapeutic target.

Topics & Concepts

Immune systemMicrovesiclesTumor microenvironmentDendritic cellBiologyCell biologyLipid metabolismPeroxisome proliferator-activated receptorMitochondrial biogenesisCancer researchImmunotherapyMitochondrionImmunologyReceptormicroRNABiochemistryGeneExtracellular vesicles in diseaseImmune cells in cancerAutophagy in Disease and Therapy
PPARα Inhibition Overcomes Tumor-Derived Exosomal Lipid-Induced Dendritic Cell Dysfunction | Litcius